Search the Newsreel

Valion Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Valion Bio (Nasdaq:VBIO) - analisi del titolo

This article provides an analysis of Valion Bio (Nasdaq: VBIO), an advanced-stage biopharmaceutical company with a market capitalization of US$546.7k. The company is developing Entolimod for Acute Radiation Syndrome (ARS) and oncology supportive care, facing significant risks including a highly volatile stock price, declining …

Entolimod Could Receive Its First National Registration in Ukraine

Valion Bio (Nasdaq: VBIO) announced that Ukraine's Ministry of Health has accepted the regulatory dossier for its ARS countermeasure, Entolimod, for formal review. A favorable decision, which could come as early as Q4 2026, would mark Entolimod's first national registration and could lead to …

Valion Bio, Inc. SEC Filing (Aug 13, 2026)

This article reports on Valion Bio, Inc.'s SEC Filing of type EFFECT on August 13, 2026. The filing has a neutral impact and sentiment, indicating that it is a routine notice of effectiveness for an S-1 registration form. The filing concerns Valion Bio, Inc. …

Valion Bio Inc. (VBIO) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength

This article provides a company profile for Valion Bio Inc. (VBIO), detailing its operations as a bio-electronic health-tech company developing micro current therapy solutions. It includes key financial facts such as market capitalization, 52-week high and low prices, current and previous day's stock prices, …

Valion Bio begins safety study for radiation injury drug By Investing.com

Valion Bio Inc. (NASDAQ:VBIO) is commencing a safety study for its drug Entolimod, aimed at treating radiation-induced gastrointestinal injury. The study, funded by a government program, will confirm the drug's tolerability in animals, with a therapeutic study to follow and top-line data expected in …

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio announced that the U.S. government is funding studies through AFRRI/NIAID to evaluate Entolimod for radiation-induced gastrointestinal (GI) injury. These studies, including a safety study starting this week and a therapeutic study to follow, aim to determine Entolimod's effectiveness in supporting survival and …

Valion Bio Plans Mouse Study After Lethal Radiation Exposure

Valion Bio (Nasdaq: VBIO) announced that the U.S. government-funded Armed Forces Radiobiology Research Institute (AFRRI) program, under a NIAID contract, will begin evaluating Entolimod for lethal radiation-induced gastrointestinal (GI) injury. A safety study is set to start this week, followed by a therapeutic study …

Valion Bio, Inc. (OTC: VBIO) investors file 13D/A and outline $9M preferred stock plan

A Valion Bio, Inc. shareholder group, including 3i, LP, Tumim Stone Capital, 3i Management, and Maier J. Tarlow, has filed an amended Schedule 13D, disclosing beneficial ownership of 9.9% of the company's common stock. The amendment reveals a proposal by 3i, LP to invest …

Valion Bio, Inc. - Common stock (Nasdaq:VBIO) Stock Quote

This article provides a stock quote for Valion Bio, Inc. (Nasdaq: VBIO), showing its current trading information, including price, volume, and performance metrics. It also features recent news headlines related to the company, such as a press release about U.S. government-funded Entolimod studies, and …

Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone

Valion Bio (VBIO) has entered into a Securities Purchase Agreement with Avenue Venture Opportunities Fund to issue Series A Preferred Stock. This agreement serves as partial consideration for a $750,000 milestone payment under a previous license agreement. The company also issued additional Series A …

Insiders Who Sold Valion Bio Missed Out On 19% Stock Increase

Valion Bio (NASDAQ:VBIO) stock recently gained 19%, but insiders who sold US$368k worth of shares at an average price of US$0.71 over the past year are still considered better off as this price is higher than the current US$0.33. While insider selling was significant, …

Valion Bio (VBIO) backer 3i builds 9.9% stake and urges CEO replacement

An investor group led by 3i, LP, Tumim Stone Capital, LLC, 3i Management LLC, and Maier J. Tarlow has acquired a 9.9% beneficial ownership in Valion Bio (VBIO). The group, which has provided substantial financing to Valion Bio, has shifted their filing to a …

3i, LP Pushes for Changes at Valion Bio with 9.9% Stake

3i, LP has acquired a 9.9% stake in Valion Bio, Inc., transitioning from a passive investor to an activist one. The firm is demanding the immediate removal of Valion Bio's CEO, Michael Handley, and is open to further actions including buying or selling more …

Valion Bio Inc (NASDAQ: VBIO) Share Price, VBIO Stock News, VBIO Share Price & Updates

Murchinson Ltd. Acquires 440,242 Shares in Valion Bio Inc.

Murchinson Ltd. has acquired 440,242 shares of Valion Bio Inc. at $0.765 per share, making it a new holding in their portfolio. Valion Bio Inc. is a late-stage biopharmaceutical company with a market cap of $915,000, facing financial challenges despite its innovative product pipeline. …

Planned cancer trial will test whether Entolimod protects marrow

Valion Bio (Nasdaq: VBIO) announced that Sheba Medical Center will fund and conduct a clinical trial to evaluate Entolimod in cancer patients receiving high-dose radiation for a rare cancer. This collaboration provides a second clinical development pathway for Entolimod, expanding its potential application into …

Price to earnings forward of Valion Bio, Inc. – NASDAQ:VBIO

Valion Bio Reports Q1 2026 Earnings and Strategic Outlook

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

Valion Bio Inc. (VBIO) Live Share Price, Invest From India

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model